1800 244 735

Helpline (02) 9874 9777

Illuminating the progression of Huntington’s disease

Huntington’s disease (HD) progression is a long process in which the first changes in the brain happen well before we even see symptoms in patients. It makes sense to focus our efforts on treating the earliest changes, to nip the problem in the bud. But what are these changes and how can we target them? A recent study has literally shed some light on this question. By creating HD mice with glowing brain cells, researchers at the University of Nottingham Medical School and the Babraham Institute in the UK have found that some of the earliest changes happen before these cells start to die, in a region of the brain where HD researchers have never before thought to look.

Turn on the magic of colored light

The mice in question have but a small percentage of brain cells, called neurons, lit up, and for good reason. Neurons can be thought of as miniature information processors that receive incoming signals at input structures called “dendrites”, process the information in the cell body or “soma”, and transmit the signal down a long thin wire called the “axon”.

The information is relayed to the next neuron’s dendrites to propagate messages throughout a vastly complex network — messages that coordinate our every thought, action, and bodily function. This complexity means that neurons are densely packed in amongst all kinds of other cells and material in the brain. So, much like the nostalgic Lite-Brite toy, illuminating a small subset of neurons and leaving the rest dark allows a clear picture to emerge.

Another reason neurons are difficult to study in the brain is that a neuron’s “output wire”, or axon, can run long distances. The neurons that control your body’s movements, for example, have their soma in the cortex, but send their axons all the way down to the spinal cord. That’s a long trip for a tiny cell!

Lighting up one entire cell allows investigators to trace an individual neuron from its dendritic input points, through the soma, all along the axon to its final destination in another brain area. This means they can ask whether abnormalities in an axon are associated with changes in the rest of the cell to which that specific axon belongs. Knowing which part of the neuron gets sick first could help scientists understand what processes go wrong earliest in HD.

The neurons of two different HD mouse models were illuminated in this way: one “transgenic” model and another “knock-in” model. The specific transgenic mouse they used has been engineered to carry a small chunk of the mutant HD gene. The knock-in mouse, on the other hand, has the HD-causing expansion “knocked-in” to its natural mouse version of the huntingtin gene.

The major difference between these two mouse models is the speed and severity with which they get sick. The transgenic model progresses much faster (showing symptoms at 12 weeks versus 12 months), which can be advantageous, for example to get quicker answers about potential drug compounds. The knock-in model takes much longer to get sick and has less drastic (sometimes more difficult-to-measure) symptoms, but more closely resembles what happens with HD patients, making it a more accurate model. Often in research, there’s a trade-off between accuracy and speed, and that’s the case with these two different models.

Bulges in the wire

While HD is a brain disease, the problems found in HD are not evenly distributed throughout the brain. Cells in certain brain regions are known to get sick and die earlier than others. A small region deep within the brain called the “striatum” is the most vulnerable part of the brain in HD, almost disappearing during the course of disease.

To study this brain area in HD mice, the research team compared the glowing neurons in each model at their respective early and late stages of disease. Surprisingly, in the transgenic mice, neurons of the striatum were found to be normal and healthy, despite the fact that the mice had a number of symptoms. This suggests that other factors, besides the obvious death or dysfunction of neurons in the striatum, must cause the HD-like symptoms seen in these mice.

As for the knock-in model, while the early-stage mice had normal, healthy-looking brain cells in their striatum, the late-stage mice showed regions of bulgy swelling in their axons. Axons, remember, are the transmitting wire of the neuron, carrying it’s message out to other cells in the brain.

Axonal swelling happens naturally during aging and in some brain diseases, but it happened earlier and more often in knock-in HD mice. Each axon’s corresponding soma (cell body) and dendrites (input structures), meanwhile, still looked healthy. This is very interesting, because it suggests that in this accurate mouse model, changes in the axon are the first to be seen.

If we assume that this mild mouse model represents an early stage of what goes wrong in the HD brain, these results might help us focus our energy on studying the right part of the neuron, particularly the axon. There is significant evidence of problems in axons in HD, and these results add support to the idea that these problems are worth understanding in HD.

The researchers weren’t content to study only changes in the striatum, however, they looked widely at other brain regions in hopes of identifying other early changes in the HD brain. Surprisingly, the region with the most axonal swelling was a structure near the striatum called the stria terminalis, which is involved in anxiety-related behavior.

Axons in the stria terminalis showed swelling even at the early stages of disease progression, and it got worse at late stages. Once again, each affected axon could be traced back to its soma (in yet another brain region called the amygdala), and these cell bodies were still healthy. This suggests that this brain region is also worthy of additional attention in HD.

A gramme in time saves nine

We never get tired of saying that even genetically modified mice are not HD patients, and no mouse model will be able to tell us everything about what’s happening in the HD brain. But the results of this study tell us that, at least in a model more similar to HD, axons show degeneration before the other neuron bits do. We need to think about which parts of the cell are sick before we can think about how to treat them, and while the knock-in mouse model has its limitations, it’s a good place to study axon degeneration during HD.

This work also tells us that the first site of decline in the HD brain may not be the striatum after all. To be sure, we may be missing some important information since not all of the neurons of the striatum were made visible by the glowing trick. But we certainly have a new brain region to explore, and if turns out to be the opening scene for degeneration, then it will make an attractive target for therapies that can stop the damage before it starts.

Share on facebook
Share on twitter
Share on pinterest
Share on email

Latest Research Articles

Scientists identify precisely how pridopidine works in models of Huntington’s disease

Published date: 12 June, 2021

Pridopidine is a drug developed to treat Huntington’s disease (HD) and now scientists have a clearer understanding of how it works in the body and brain. In a series of academic papers, researchers figured out that pridopidine is working by targeting a particular receptor protein called S1R. With this new understanding, the researchers believe pridopidine ... Read more

Huntington's disease therapeutics conference 2021 – Day 3

Published date: 29 April, 2021

We are back for the last day of the virtual 2021 CHDI Therapeutics conference. This article summarises our live Twitter updates on the exciting science being presented, which you can find with the hashtag #HDTC2021. The final session of the conference will provide the latest news on more Huntington’s disease clinical programs. A new way ... Read more

Huntington's disease therapeutics conference 2021 – Day 2

Published date: 28 April, 2021

We are back with Day 2 of the virtual 2021 CHDI Therapeutics conference. This article summarises our live Twitter updates on the exciting science being presented, which you can continue to follow with the hashtag #HDTC2021. The morning session focussed on promising HD therapeutics that are in preclinical development and the afternoon session covered different ... Read more

Huntington’s disease therapeutics conference 2021 – Day 1

Published date: 28 April, 2021

The CHDI Therapeutics Conference 2021 kicked off today. This article summarizes our live Twitter updates on the exciting science being presented, which you can continue to follow with the hashtag #HDTC2021. The morning of Day 1 focused on clinical trial updates, while the afternoon explored genetic modifiers of HD and how they might be harnessed ... Read more

Huntington’s disease clinical trial round up

Published date: 26 April, 2021

It seems like the HD community has been inundated with updates from different companies and clinical trials recently. The news is far from complete doom and gloom; although there have been some real disappointments from some of the frontrunner trials, there are also positive updates from many different companies and lots of reasons for us ... Read more

Good news from uniQure: gene therapy trial on track, and promising data in animals

Published date: 15 April, 2021

Two recent press releases from uniQure provide welcome good news: the first ever HD gene therapy, known as AMT-130, has been administered via brain surgery to a small set of participants in an early safety trial. At the same time, uniQure has published findings in HD animal models that increase confidence in the drug’s ability ... Read more